Overview of China's Market Approval Policy Med Insurance Payment System

Published on: Apr 7, 2022

Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.

In this whitepaper, hear from Parexel rare disease consultants on the following topics:

  • Relevant Policies on Expedited Approval of Rare Disease Drugs 
  • An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs

Open PDF

Return to Insights Center

Related Insights

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance

Jun 17, 2025

Webinar

China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023

Blog

Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?

Jun 14, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Playbook

Insights from the 2022 R&D Innovation Survey

Feb 17, 2023

Related Insights

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance

Jun 17, 2025

Webinar

China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Show more